Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals is a biopharmaceutical company that focuses on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus on oncology. It has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.

Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority

Qylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)

Qylur Awarded SBIR Phase II Contract for Tactical AI Spectrum Classifier Systems (TASCS)

NanoViricides

NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which has shown promise in treating various viral infections including RSV, COVID-19, and Influenza in animal studies, could revolutionize the treatment of respiratory viruses, according to the company.

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387

Press Release STALICLA's precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptoms Geneva, Switzerland – June 27, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neuropsychiatric and neurodevelopmental disorders, today announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder (ASD), named ASD Phenotype 1 (ASD-Phen1). The results of the study were published in the peer-reviewed journal Biomedicines, in an article titled “Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD”.

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that it has completed enrollment in its Phase 1 trial (NCT06128382) with OVX033, the company's broad-spectrum vaccine candidate against sarbecoviruses. The study is designed to evaluate the safety and immunogenicity of OVX033 at three dose levels (100µg, 250µg and 500µg). To date, no safety concerns or signals ha.

Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033

St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus following administration of Neumifil. These data were featured during an oral presentation* at the American Thoracic Society (ATS) in San Diego on 21st May.

Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference

Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announces that clinical results from a human challenge study with Neumifil (HEX17) will be presented at the 2024 American Thoracic Society (ATS) Conference, which will be held virtually and in person in San Diego, CA, May 17-22. The data will be presented in both oral and ePoster presentation sessions and will highlight important clinical results about the company's proprietary drug, Neumifil.

Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024

NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, with no adverse events reported in any of the three dose levels from the two formulations used in the study, namely NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies.

NanoViricides completes Phase 1a/1b human clinical trial for its broad-spectrum antiviral drug

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate.

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

St Andrews, UK – 2nd October 2023 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announced positive results from its Phase 2, Proof of Concept, Controlled Human Infection Model (CHIM) study where patients were challenged with influenza virus following administration of Neumifil.

Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study

LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet Infectious Diseases published results from the company's OVX836-003 study under the title, “Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomised, double-blind placebo-controlled, Phase 2a trial.” The research.

Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836

Spectrum stockholders will receive contingent value rights, too, along with Assertio shares. The rewards are payable on achievement of 2024 and 2025 sales levels from Spectrum's lead drug. Rolvedon has already reached the first (hardest) target in Q1 without the help of a J-Code that took effect at the beginning of Q2.

Buy Spectrum Pharmaceuticals For Exposure To Assertio Holdings

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”) announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have each recommended that Spectrum stockholders vote “FOR” the proposal to adopt the Agreement and Plan of Merger (“Merger Agreement”, and such proposal, the “Merger Proposal”) at the upcoming special meeting of stockholders (the “Speci.

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.

Assertio Therapeutics Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) to Assertio Holdings, Inc. (NasdaqCM: ASRT). Under the terms of the proposed transaction, shareholders of Spectrum will receive, for each share of Spectrum that they own, 0.1783 shares of Assertio and one contingent value right for the right to receive $0.10 paya.

SPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI

Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Spectrum's ROLVEDON has the potential to become the standard of care for reducing chemotherapy-induced neutropenia in a $3B domestic market. The combined companies of Assertio and Spectrum are estimated to provide a return of 4x.

Spectrum's Rolvedon A Differentiator In A $3B/Yr Market

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company previously receiv.

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Spectrum Pharmaceuticals (SPPI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.

Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update. First Quarter 2023 and Recent Business Update Net sales for Q1 2023 totaled $15.6 million, an increase of 54% compared to Q4 2022. 172 targeted accounts purchased ROLVEDON™ (eflapegrastim-xnst) Injection during the.

Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

Aditxt Inc

Clover Health Investments

Novo Integrated Sciences, Inc.

OPKO Health

Senseonics Holdings

Tuya

Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1.10 To Watch This Week

Penny stocks to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Under $1.10 To Watch Now

NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. ("Spectrum Pharmaceuticals" or the "Company") (NASDAQ: SPPI), in connection with its acquisition by Assertio Holdings, Inc. (NASDAQ: ASRT) ("Assertio"). Under the merger agreement, the Company's shareholders will receive 0.1783 shares of Assertio common stock for each of their shares, representing implied per-share consideration of $0.89 based upon Assertio's April 26, 2023 closing price of $5.00.

SHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.

NEW YORK , April 27, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), in connection with its proposed merger with Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum Pharmaceuticals"). If you own Assertio  shares  and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: https://www.weisslaw.co/news-and-cases/asrt   Or please contact: Joshua Rubin, Esq.

SHAREHOLDER ALERT: Weiss Law Investigates Assertio Holdings, Inc.

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning.  The $248 million purchase price values Spectrum shares at $1.14 each, a significant premium over its Tuesday closing price of $0.69.

Spectrum Pharmaceuticals stock pops after Assertio acquires it at a premium

MILWAUKEE , April 25, 2023 /PRNewswire/ -- Ademi LLP is investigating Spectrum (NASDAQ: SPPI) for possible breaches of fiduciary duty and other violations of law in its transaction with Assertio.  Click here to learn how to join the action https://www.ademilaw.com/case/spectrum-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Spectrum Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Assertio

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) to Assertio Holdings, Inc. is fair to Spectrum shareholders. Under the terms of the agreement, Spectrum shareholders will receive: (1) 0.1783 shares of Assertio common stock for each share of Spectrum common stock they own; and (2) one contingent value right per Spectrum share for the right to receive $0.10 payable upon ROLVEDON net sales (.

News for Spectrum Pharma Stock (SPPI)